combine@alvar.ug

Determine TB –LAM Lateral Flow Assay, Does M. tuberculosis lineage influence its performance?

Determine TB –LAM Lateral Flow Assay, Does M. tuberculosis lineage influence its performance?

Show simple record

dc.contributor.author Willy Ssengooba
dc.contributor.author Lydia Nakiyingi
dc.contributor.author Edgar Kigozi
dc.contributor.author Yukari C. Manabe
dc.contributor.author Moses L. Joloba
dc.date.accessioned 2021-01-11T13:51:45Z
dc.date.available 2021-01-11T13:51:45Z
dc.date.issued 2019
dc.identifier.uri https://combine.alvar.ug/handle/1/49546
dc.description.abstract Abstract; Background The World Health Organization conditionally recommended the Determine lateral flow TB-LAM (LF-LAM) assay for tuberculosis diagnosis. The test is recommended for diagnosis and screening of active tuberculosis among HIV-infected individual’s adults with signs and symptoms of TB (pulmonary and/or extra pulmonary) with CD4 cell count less than or equal to 100 cells/mm3 or HIV-positive patients who are seriously ill, regardless of CD4 cell counts. However, the effect of MTB genetic diversity to the performance of LF-LAM remains unknown. We determined the perfomance of the against M. tuberculosis (MTB) lineages among HIV-positive individuals with pulmonary and/or MTB-bacteremia. Methods In a retrospective study, of 68 patients culture-positive for MTB, we used spoligotyping and/or MIRU-VNTR methods to determine the MTB-lineages. Patients 51 had both pulmonary and MTB-bacteremia and 17 patients had exclusively PTB. We compared the performance of LF-LAM against MTB-lineage in blood and sputum samples. LF-LAM performance was also analyzed in presence of mixed MTB-infection and patient CD4 cell count. Results The median age (interquartile range; IQR) of participants was 32 (30-35) and only sixty-six patients had CD4 results. The median (IQR) CD4 cell count/mm3 was 27(18-34). MTB-lineages in sputum were; CAS (L3) 17/68 (25%) and Euro-American-lineage (L4) 55/68 (75%) whereas in blood were L3 7/51 (13.7%) and L4 44/51 (86.3%). Among patients with TB-bacteraemia, LF-LAM was positive 100% for L3 and 32/44 (73%) for L4. LF-LAM was 100% positive among exclusively PTB patients with L3 and L4. The results did’not change by presence of mixed MTB-infection. Categroizing patients as CD4 <50 and ≥50 cell/mm3. All 100% of L3 strains remained with a positive LF-LAM test in both categories whereas 11 (68.7%) and 30 (82%) of the patients with CD >50 and ≤50 cells/mm3 respectively, with L4 had a positive LF-LAM test. Conclusions Our study show that L3 may have more specificity for LF-LAM assay than L4. Regional diversity in performance of LF-LAM assay may occur depending on the dorminat MTB lineage. Future studies on a large sample size with more MTB-lineage diversity are recommended.
dc.publisher Research Square
dc.title Determine TB –LAM Lateral Flow Assay, Does M. tuberculosis lineage influence its performance?
dc.type Preprint
dc.identifier.doi 10.21203/rs.2.9331/v1
dc.identifier.lens 052-917-941-085-060


This record appears in the collections of the following institution(s)

Show simple record

Search Entire Database


Browse

My Account